Postow, Michael A <br/><br/>
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?  [electronic resource] 

 -  Clinical advances in hematology & oncology : H&O  May 2018 
 - 353-355 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1543-0790 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Chemotherapy, Adjuvant--methods<br/>Combined Modality Therapy--methods<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Imidazoles--therapeutic use<br/>Immunotherapy--methods<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Ipilimumab--therapeutic use<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>Melanoma--drug therapy<br/>Nivolumab<br/>Oximes--therapeutic use<br/>Prognosis<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Pyridones--therapeutic use<br/>Pyrimidinones--therapeutic use<br/>Randomized Controlled Trials as Topic<br/>Recombinant Proteins--therapeutic use<br/>Recurrence<br/>Skin Neoplasms--drug therapy<br/>Survival Analysis